Methyl salicylate

Identification

Name
Methyl salicylate
Accession Number
DB09543
Type
Small Molecule
Groups
Approved, Vet approved
Description

Methyl salicylate (oil of wintergreen or wintergreen oil) is an organic ester naturally produced by many species of plants, particularly wintergreens. The compound was first extracted and isolated from plant species Gaultheria procumbens in 1843. It is also synthetically produced, used as a fragrance, in foods and beverages, and in liniments. It forms a colorless to yellow or reddish liquid and exhibits a characteristic odor and taste of wintergreen. For acute joint and muscular pain, methyl salicylate is used as a rubefacient and analgesic in deep heating liniments. It is used as a flavoring agent in chewing gums and mints in small concentrations and added as antiseptic in mouthwash solutions.

Structure
Thumb
Synonyms
  • 2-(Methoxycarbonyl)phenol
  • 2-Carbomethoxyphenol
  • 2-Hydroxybenzoic acid methyl ester
  • Betula oil
  • Gaultheria oil
  • Methyl 2-hydroxybenzoate
  • Methyl o-hydroxybenzoate
  • Natural wintergreen oil
  • Oil of wintergreen
  • Spicewood Oil
  • Sweet birch oil
  • Teaberry oil
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
SportgelEmulsion10 %TopicalMeyer Zall Laboratories Pty Ltd.Not applicableNot applicableCanada
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Aspi-Rub Pain RelieverSpray23 g/100gTopicalAspi Rub Enterprises Llc2014-08-29Not applicableUs
Balsamo de Ubre MascuraOintment10.5 g/90gTopicalMenper Distributors2011-05-10Not applicableUs
Bumooly-SSolution3 g/100mLTransdermalScott Holdings Co., Ltd.2014-05-16Not applicableUs
Bumooly-SSolution3 g/100mLTransdermalScott Holdings Co., Ltd.2014-09-25Not applicableUs
Coats Aloe AnalgesicLotion10 g/100mLTopicalTychasis Corporation2015-11-02Not applicableUs
Coats Aloe AnalgesicLotion10 g/gTopicalTychasis Corporation2015-09-29Not applicableUs
Foot Works Arthritis Achy Foot and MuscleCream250 mg/mLTopicalNew Avon Llc2012-05-30Not applicableUs
Humco Wintergreen OilLiquid980 mg/mLTopicalHumco Holding Group. Inc.1998-03-252021-10-31Us
Hyundai Moolpas FSolution3 g/100mLTransdermalScott Holdings Co., Ltd.2014-05-16Not applicableUs
Hyundai Moolpas FSolution3 g/100mLTransdermalScott Holdings Co., Ltd.2014-09-25Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
701 Dieda Zhengtong Yaogao Medicated PlasterMethyl salicylate (10 g/1) + Camphor (3.1 g/1) + Menthol (8 g/1)PlasterTopical; TransdermalGUANGZHOU BAIYUNSHAN PHARMACEUTICAL CO., LTD. BAIYUNSHAN HEJIGONG PHARMACEUTICAL FACTORY2001-10-15Not applicableUs
AA Top MedicatedMethyl salicylate (.05 g/mL) + Menthol (.1 g/mL)OilTopicalAlbert Max, Inc.2018-02-01Not applicableUs
Advanced AntisepticMethyl salicylate (.06 kg/100L) + Eucalyptol (.092 kg/100L) + Menthol (.042 kg/100L) + Thymol (.064 kg/100L)MouthwashOralDemoulas Supermarkets, Inc.2010-07-22Not applicableUs
Advanced AntisepticMethyl salicylate (.06 mL/100L) + Eucalyptol (.042 mL/100L) + Menthol (.042 mL/100L) + Thymol (.064 mL/100L)MouthwashOralWakfern Food Corporation2010-11-24Not applicableUs
Advanced Antiseptic CitrusMethyl salicylate (.06 mL/100L) + Eucalyptol (.092 mL/100L) + Menthol (.042 mL/100L) + Thymol (.042 mL/100L)MouthwashOralH.E.B.2010-10-15Not applicableUs
Advanced Antiseptic CitrusMethyl salicylate (.06 mL/100L) + Eucalyptol (.092 mL/100L) + Menthol (.042 mL/100L) + Thymol (.042 mL/100L)MouthwashOralDrug Mart1991-06-15Not applicableUs
Advanced CitrusMethyl salicylate (.06 kg/100L) + Eucalyptol (.092 kg/100L) + Menthol (.042 kg/100L) + Thymol (.064 kg/100L)MouthwashOralWalmart Stores2010-07-22Not applicableUs
Advanced Citrus AntisepticMethyl salicylate (.06 mL/100L) + Eucalyptol (.092 mL/100L) + Menthol (.042 mL/100L) + Thymol (.064 mL/100L)MouthwashOralPublix Supermarkets, Inc.2001-05-03Not applicableUs
Ageless Pain ReliefMethyl salicylate (140 mg/mL) + Menthol (70 mg/mL)CreamTopicalIsagenix International, Llc2011-04-23Not applicableUs
AIM Muscle Pain Relief CreamMethyl salicylate (10 g/100g) + Camphor (2.5 g/100g) + Menthol (1.5 g/100g)CreamTopicalLaboratorios Bremer, S.A.2018-01-04Not applicableUs
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
1st Medxpatch With Lidocaine 4%Methyl salicylate (20 1/1) + Capsaicin (.0375 1/1) + Lidocaine (4 1/1) + Menthol (5 1/1)PatchTopical1 St Medx Llc2018-03-15Not applicableUs
1st Medxpatch With Lidocaine 4%-rxMethyl salicylate (20 1/1) + Capsaicin (.0375 1/1) + Lidocaine (4 1/1) + Menthol (5 1/1)PatchTopical1 St Medx Llc2018-03-15Not applicableUs
AdazinMethyl salicylate (1 g/100g) + Benzocaine (2 g/100g) + Capsaicin (.035 g/100g) + Lidocaine (2 g/100g)CreamTopicalSterling Knight Pharmaceuticals, Llc2014-12-03Not applicableUs
Antiphlamine Coin PlasterMethyl salicylate (5.541 mg/.2832g) + DL-alpha-Tocopherol (.308 mg/.2832g) + Diphenhydramine (.246 mg/.2832g) + Menthol (2.769 mg/.2832g) + Nonivamide (.046 mg/.2832g) + Peppermint oil (.693 mg/.2832g) + Synthetic Camphor (1.108 mg/.2832g)PatchTopicalHanul Trading Co., Ltd.2016-10-10Not applicableUs
Antiseptic RinseMethyl salicylate (.06 kg/100L) + Eucalyptol (.092 kg/100L) + Menthol (.042 kg/100L) + Thymol (.064 kg/100L)MouthwashOralMeijer2006-08-08Not applicableUs
Comfort EZ Extra Strength Pain Relief PatchMethyl salicylate (20 g/100g) + Lidocaine (4 g/100g) + Menthol (1 g/100g)PatchTopicalSimple Diagnostics. Inc.2015-03-062015-12-29Us
Comfort EZ Extra StrengthTransdermal PatchMethyl salicylate (2 g/100g) + Lidocaine hydrochloride (4 g/100g) + Menthol (1 g/100g)PatchTopicalSimple Diagnostics. Inc.2015-03-232015-12-29Us
Comfort EZ Pain Relief PatchMethyl salicylate (16 g/100g) + Lidocaine (4 g/100g) + Menthol (2 g/100g)PatchTopicalSimple Diagnostics. Inc.2014-11-182015-12-29Us
Dolor-parche With Lidocaine-RXMethyl salicylate (20 g/1) + Capsaicin (.035 g/1) + Lidocaine (.5 g/1) + Menthol (5 g/1)PatchTopicalTwo Hip Consulting, Llc2013-07-312016-10-13Us
Doloracin RxMethyl salicylate (20 g/100mL) + Capsaicin (.035 g/100mL) + Menthol (5 g/100mL)CreamTopicalTwo Hip Consulting, Llc2013-08-112016-10-13Us
Categories
UNII
LAV5U5022Y
CAS number
119-36-8
Weight
Average: 152.1473
Monoisotopic: 152.047344122
Chemical Formula
C8H8O3
InChI Key
OSWPMRLSEDHDFF-UHFFFAOYSA-N
InChI
InChI=1S/C8H8O3/c1-11-8(10)6-4-2-3-5-7(6)9/h2-5,9H,1H3
IUPAC Name
methyl 2-hydroxybenzoate
SMILES
COC(=O)C1=CC=CC=C1O

Pharmacology

Indication

Ointments or liniments containing methyl salicylate are applied topically as counter irritant for relief of acute pain associated with lumbago,sciatica and rheumatic conditions. Local analgesics for human and veterinary medicine.

Associated Conditions
Pharmacodynamics

Methyl salicylate relieve musculoskeletal pain in the muscles, joints, and tendons by causing irritation and reddening of the skin due to dilated capillaries and increased blood flow. It is pharmacologically similar to aspirin and other NSAIDs but as a topical agent it primarily acts as a rubefacient and skin irritant. Counter-irritation is believed to cause a soothing sensation of warmth.

Mechanism of action

Counter-irritation is thought to be effective at alleviating musculoskeletal pain as the irritation of the sensory nerve endings is thought to alter or offset pain in the underlying muscle or joints that are served by the same nerves [5]. This is thought to mask the underlying musculoskeletal pain and discomfort. When applied topically, methyl salicylate is thought to penetrate the skin and underlying tissues where it reversibly inhibits cyclooxygenase enzyme and locally and peripherally prevents the production of inflammatory mediators such as prostaglandin and thromboxane A2.

Absorption

Approximately 12-20% of topically applied methyl salicylate may be systemically absorbed through intact skin within 10 hours of application, and absorption varies with different conditions such as surface area and pH. Dermal bioavailability is in the range of 11.8 – 30.7%. For the assessment of potential oral exposure to salicylates, bioavailability is assumed to be 100% [9].

Volume of distribution

After absorption, methyl salicylate is distributed throughout most body tissues and most transcellular fluids, primarily by pH dependent passive processes. Salicylate is actively transported by a low-capacity, saturable system out of the CSF across the choroid plexus. The drug readily crosses the placental barrier.

Protein binding

Degree of albumin binding depends on the plasma concentration of the compound

Metabolism

Minor metabolism may occur in various tissues but hepatic metabolism constitutes the majority of metabolic processes of absorbed methyl salicylate. It is mainly hydrolyzed to salicylic acid via hepatic esterase enzymes. Conjugation with glycine forms salicyluric acid and conjugation with glucuronic forms ester or acyl and ether or phenolic glucuronide, which are the three main metabolites.

Route of elimination

Excreted by kidneys as free salicylic acid (10%), salicyluric acid (75%), salicylic phenolic (10%) and acyl glucuronide (5%), and gentisic acid (less than 1%).

Half life

The plasma half-life for salicylate is 2 to 3 hr in low doses and about 12 hr at usual anti-inflammatory doses. The half-life of salicylate may be as long as 15 to 30 hr at high therapeutic doses or when there is intoxication.

Clearance
Not Available
Toxicity

Oral LD50 values (mg/kg) for mouse, rat and rabbit are 1110, 887 and 1300, respectively. Oral LD50 values for child and adult human (mg/kg) are 228 and 506, respectively. Although systemic toxicity from topical administration is rare, methyl salicylate can be absorbed in intract skin to cause stimulation of the central nervous system respiratory center, disturbance of lipid and carbohydrate metabolism, and disturbance of intracellular respiration. Severe toxicity can result in acute lung injury, lethargy, coma, seizures, cerebral edema, and death. In case of salicylate poisoning, the treatment consists of general supportive care, gastrointestinal decontamination with activated charcoal in cases of salicylate ingestion, and monitoring of serum salicylate concentrations. Bicarbonate infusions or hemodialysis can be used to achieve enhanced salicylate elimination [7].

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(R)-warfarinMethyl salicylate may increase the anticoagulant activities of (R)-warfarin.Experimental
(S)-WarfarinMethyl salicylate may increase the anticoagulant activities of (S)-Warfarin.Experimental, Investigational
2,4-thiazolidinedioneMethyl salicylate may increase the hypoglycemic activities of 2,4-thiazolidinedione.Investigational
4-hydroxycoumarinMethyl salicylate may increase the anticoagulant activities of 4-hydroxycoumarin.Experimental
AbciximabThe risk or severity of bleeding can be increased when Methyl salicylate is combined with Abciximab.Approved
AcarboseMethyl salicylate may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AceclofenacThe therapeutic efficacy of Methyl salicylate can be decreased when used in combination with Aceclofenac.Approved, Investigational
AcenocoumarolMethyl salicylate may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
AcetazolamideThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Acetazolamide.Approved, Vet Approved
AcetohexamideMethyl salicylate may increase the hypoglycemic activities of Acetohexamide.Approved, Investigational, Withdrawn
AcetyldigitoxinThe serum concentration of Acetyldigitoxin can be decreased when it is combined with Methyl salicylate.Approved
AcetyldigoxinThe serum concentration of Acetyldigoxin can be decreased when it is combined with Methyl salicylate.Experimental
Acetylsalicylic acidThe risk or severity of bleeding can be increased when Methyl salicylate is combined with Acetylsalicylic acid.Approved, Vet Approved
AICA ribonucleotideMethyl salicylate may increase the hypoglycemic activities of AICA ribonucleotide.Experimental, Investigational
AlbiglutideMethyl salicylate may increase the hypoglycemic activities of Albiglutide.Approved
AlclometasoneThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Aldosterone.Experimental, Investigational
AlogliptinMethyl salicylate may increase the hypoglycemic activities of Alogliptin.Approved
AloxiprinThe risk or severity of bleeding, nephrotoxicity, and gastrointestinal bleeding can be increased when Aloxiprin is combined with Methyl salicylate.Experimental
AlteplaseThe risk or severity of bleeding can be increased when Methyl salicylate is combined with Alteplase.Approved
AmcinonideThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Amcinonide.Approved
AmediplaseThe risk or severity of bleeding can be increased when Methyl salicylate is combined with Amediplase.Investigational
AMG-222Methyl salicylate may increase the hypoglycemic activities of AMG-222.Investigational
Aminosalicylic AcidThe risk or severity of bleeding, nephrotoxicity, and gastrointestinal bleeding can be increased when Aminosalicylic Acid is combined with Methyl salicylate.Approved
Ammonium chlorideThe serum concentration of Methyl salicylate can be increased when it is combined with Ammonium chloride.Approved, Investigational, Vet Approved
AnagliptinMethyl salicylate may increase the hypoglycemic activities of Anagliptin.Investigational
AnagrelideThe risk or severity of bleeding can be increased when Methyl salicylate is combined with Anagrelide.Approved
AncrodThe risk or severity of bleeding can be increased when Methyl salicylate is combined with Ancrod.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Methyl salicylate.Investigational
AnistreplaseThe risk or severity of bleeding can be increased when Methyl salicylate is combined with Anistreplase.Approved
AntipyrineThe therapeutic efficacy of Methyl salicylate can be decreased when used in combination with Antipyrine.Approved, Investigational
Antithrombin III humanThe risk or severity of bleeding can be increased when Methyl salicylate is combined with Antithrombin III human.Approved
AntrafenineThe therapeutic efficacy of Methyl salicylate can be decreased when used in combination with Antrafenine.Approved
ApixabanThe risk or severity of bleeding can be increased when Methyl salicylate is combined with Apixaban.Approved
ArdeparinThe risk or severity of bleeding can be increased when Methyl salicylate is combined with Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanThe risk or severity of bleeding can be increased when Methyl salicylate is combined with Argatroban.Approved, Investigational
AstaxanthinThe risk or severity of bleeding can be increased when Methyl salicylate is combined with Astaxanthin.Investigational
AzathioprineThe metabolism of Azathioprine can be decreased when combined with Methyl salicylate.Approved
AzosemideThe therapeutic efficacy of Azosemide can be decreased when used in combination with Methyl salicylate.Investigational
BalaglitazoneMethyl salicylate may increase the hypoglycemic activities of Balaglitazone.Investigational
BalsalazideThe risk or severity of bleeding, nephrotoxicity, and gastrointestinal bleeding can be increased when Balsalazide is combined with Methyl salicylate.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Beclomethasone dipropionate.Approved, Investigational
BemiparinThe risk or severity of bleeding can be increased when Methyl salicylate is combined with Bemiparin.Approved, Investigational
Bempedoic acidMethyl salicylate may increase the hypoglycemic activities of Bempedoic acid.Investigational
BenazeprilThe risk or severity of renal failure can be increased when Methyl salicylate is combined with Benazepril.Approved, Investigational
BenazeprilatThe risk or severity of renal failure can be increased when Methyl salicylate is combined with Benazeprilat.Experimental
BenfluorexMethyl salicylate may increase the hypoglycemic activities of Benfluorex.Investigational, Withdrawn
BeraprostThe risk or severity of bleeding can be increased when Methyl salicylate is combined with Beraprost.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Betamethasone.Approved, Vet Approved
BivalirudinThe risk or severity of bleeding can be increased when Methyl salicylate is combined with Bivalirudin.Approved, Investigational
BrinaseThe risk or severity of bleeding can be increased when Methyl salicylate is combined with Brinase.Experimental
BrinzolamideThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Brinzolamide.Approved
BromfenacThe therapeutic efficacy of Methyl salicylate can be decreased when used in combination with Bromfenac.Approved
BromocriptineMethyl salicylate may increase the hypoglycemic activities of Bromocriptine.Approved, Investigational
BudesonideThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Budesonide.Approved
BufexamacThe therapeutic efficacy of Methyl salicylate can be decreased when used in combination with Bufexamac.Approved, Experimental
BuflomedilThe risk or severity of adverse effects can be increased when Buflomedil is combined with Methyl salicylate.Experimental
BuforminMethyl salicylate may increase the hypoglycemic activities of Buformin.Investigational, Withdrawn
BumetanideThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Methyl salicylate.Approved
ButylphthalideThe risk or severity of adverse effects can be increased when Butylphthalide is combined with Methyl salicylate.Investigational
CanagliflozinMethyl salicylate may increase the hypoglycemic activities of Canagliflozin.Approved
CangrelorThe risk or severity of bleeding can be increased when Methyl salicylate is combined with Cangrelor.Approved
CaptoprilThe risk or severity of renal failure can be increased when Methyl salicylate is combined with Captopril.Approved
Carbaspirin calciumThe risk or severity of bleeding, nephrotoxicity, and gastrointestinal bleeding can be increased when Carbaspirin calcium is combined with Methyl salicylate.Experimental, Investigational
CarbutamideMethyl salicylate may increase the hypoglycemic activities of Carbutamide.Experimental
CarmegliptinMethyl salicylate may increase the hypoglycemic activities of Carmegliptin.Investigational
CarprofenThe therapeutic efficacy of Methyl salicylate can be decreased when used in combination with Carprofen.Approved, Vet Approved, Withdrawn
CertoparinThe risk or severity of bleeding can be increased when Methyl salicylate is combined with Certoparin.Approved, Investigational
ChlorpropamideMethyl salicylate may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
Choline magnesium trisalicylateThe therapeutic efficacy of Methyl salicylate can be decreased when used in combination with Choline magnesium trisalicylate.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Ciclesonide.Approved, Investigational
CiglitazoneMethyl salicylate may increase the hypoglycemic activities of Ciglitazone.Experimental
CilazaprilThe risk or severity of renal failure can be increased when Methyl salicylate is combined with Cilazapril.Approved
CilostazolThe risk or severity of adverse effects can be increased when Cilostazol is combined with Methyl salicylate.Approved, Investigational
ClobetasolThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Clobetasol.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Clocortolone.Approved
ClopidogrelThe risk or severity of adverse effects can be increased when Clopidogrel is combined with Methyl salicylate.Approved
CloprednolThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Cloprednol.Experimental
CloricromenThe risk or severity of adverse effects can be increased when Cloricromen is combined with Methyl salicylate.Experimental
ClorindioneMethyl salicylate may increase the anticoagulant activities of Clorindione.Experimental
CorticotropinThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Corticotropin.Approved, Investigational, Vet Approved
Cortisone acetateThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Cortisone acetate.Approved, Investigational
CortivazolThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Cortivazol.Investigational
CymarinThe serum concentration of Cymarin can be decreased when it is combined with Methyl salicylate.Experimental
Dabigatran etexilateThe risk or severity of bleeding can be increased when Methyl salicylate is combined with Dabigatran etexilate.Approved
DalteparinThe risk or severity of bleeding can be increased when Methyl salicylate is combined with Dalteparin.Approved
DanaparoidThe risk or severity of bleeding can be increased when Methyl salicylate is combined with Danaparoid.Approved, Withdrawn
DapagliflozinMethyl salicylate may increase the hypoglycemic activities of Dapagliflozin.Approved
DarexabanThe risk or severity of bleeding can be increased when Methyl salicylate is combined with Darexaban.Investigational
DefibrotideThe risk or severity of bleeding can be increased when Methyl salicylate is combined with Defibrotide.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Deflazacort.Approved, Investigational
DelaprilThe risk or severity of renal failure can be increased when Methyl salicylate is combined with Delapril.Investigational
DersalazineThe risk or severity of bleeding, nephrotoxicity, and gastrointestinal bleeding can be increased when Dersalazine is combined with Methyl salicylate.Investigational
DesirudinThe risk or severity of bleeding can be increased when Methyl salicylate is combined with Desirudin.Approved
DeslanosideThe serum concentration of Deslanoside can be decreased when it is combined with Methyl salicylate.Approved
DesmoteplaseThe risk or severity of bleeding can be increased when Methyl salicylate is combined with Desmoteplase.Investigational
DesonideThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Desoximetasone.Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Dexamethasone isonicotinate.Vet Approved
DexibuprofenThe therapeutic efficacy of Methyl salicylate can be decreased when used in combination with Dexibuprofen.Approved, Investigational
DexketoprofenThe risk or severity of bleeding and gastrointestinal bleeding can be increased when Methyl salicylate is combined with Dexketoprofen.Approved, Investigational
DextranThe risk or severity of bleeding can be increased when Methyl salicylate is combined with Dextran.Approved, Investigational, Vet Approved
DiclofenacThe therapeutic efficacy of Methyl salicylate can be decreased when used in combination with Diclofenac.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Diclofenamide.Approved, Investigational
DicoumarolMethyl salicylate may increase the anticoagulant activities of Dicoumarol.Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Diflorasone.Approved
DiflunisalThe risk or severity of bleeding, nephrotoxicity, and gastrointestinal bleeding can be increased when Diflunisal is combined with Methyl salicylate.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Difluprednate.Approved
DigitoxinThe serum concentration of Digitoxin can be decreased when it is combined with Methyl salicylate.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be decreased when it is combined with Methyl salicylate.Approved
DiltiazemDiltiazem may increase the anticoagulant activities of Methyl salicylate.Approved, Investigational
DiphenadioneMethyl salicylate may increase the anticoagulant activities of Diphenadione.Experimental
DipyridamoleThe risk or severity of bleeding can be increased when Methyl salicylate is combined with Dipyridamole.Approved
DisopyramideMethyl salicylate may increase the hypoglycemic activities of Disopyramide.Approved
DitazoleThe risk or severity of bleeding can be increased when Methyl salicylate is combined with Ditazole.Approved, Withdrawn
DorzolamideThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Dorzolamide.Approved
Drotrecogin alfaThe risk or severity of bleeding can be increased when Methyl salicylate is combined with Drotrecogin alfa.Approved, Investigational, Withdrawn
DroxicamThe therapeutic efficacy of Methyl salicylate can be decreased when used in combination with Droxicam.Withdrawn
DulaglutideMethyl salicylate may increase the hypoglycemic activities of Dulaglutide.Approved, Investigational
DutogliptinMethyl salicylate may increase the hypoglycemic activities of Dutogliptin.Investigational
Edetic AcidThe risk or severity of bleeding can be increased when Methyl salicylate is combined with Edetic Acid.Approved, Vet Approved
EdoxabanThe risk or severity of bleeding can be increased when Methyl salicylate is combined with Edoxaban.Approved
EmpagliflozinMethyl salicylate may increase the hypoglycemic activities of Empagliflozin.Approved
EnalaprilThe risk or severity of renal failure can be increased when Methyl salicylate is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of renal failure can be increased when Methyl salicylate is combined with Enalaprilat.Approved
EnglitazoneMethyl salicylate may increase the hypoglycemic activities of Englitazone.Experimental
EnoxaparinThe risk or severity of bleeding can be increased when Methyl salicylate is combined with Enoxaparin.Approved
EpoprostenolThe risk or severity of bleeding can be increased when Methyl salicylate is combined with Epoprostenol.Approved
EptifibatideThe risk or severity of adverse effects can be increased when Eptifibatide is combined with Methyl salicylate.Approved, Investigational
Etacrynic acidThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Methyl salicylate.Approved, Investigational
EthoxzolamideThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Ethoxzolamide.Withdrawn
Ethyl biscoumacetateMethyl salicylate may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtodolacThe therapeutic efficacy of Methyl salicylate can be decreased when used in combination with Etodolac.Approved, Investigational, Vet Approved
EvogliptinMethyl salicylate may increase the hypoglycemic activities of Evogliptin.Investigational
ExenatideMethyl salicylate may increase the hypoglycemic activities of Exenatide.Approved, Investigational
FenoprofenThe therapeutic efficacy of Methyl salicylate can be decreased when used in combination with Fenoprofen.Approved
Ferulic acidThe risk or severity of bleeding can be increased when Methyl salicylate is combined with Ferulic acid.Experimental
FibrinolysinThe risk or severity of bleeding can be increased when Methyl salicylate is combined with Fibrinolysin.Investigational
FlucloroloneThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Fluclorolone.Experimental
FludrocortisoneThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Fludrocortisone.Approved, Investigational
FluindioneMethyl salicylate may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumethasoneThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Flunisolide.Approved, Investigational
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Fluocinonide.Approved, Investigational
FluocortinThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Fluocortin.Experimental
FluocortoloneThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Fluorometholone.Approved, Investigational
FluperoloneThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Fluperolone.Experimental
FluprednideneThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Fluprednisolone.Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Flurandrenolide.Approved
FlurbiprofenThe therapeutic efficacy of Methyl salicylate can be decreased when used in combination with Flurbiprofen.Approved, Investigational
FluticasoneThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Fluticasone.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Fluticasone propionate.Approved
FondaparinuxThe risk or severity of bleeding can be increased when Methyl salicylate is combined with Fondaparinux.Approved, Investigational
FormocortalThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Formocortal.Experimental
FosinoprilThe risk or severity of renal failure can be increased when Methyl salicylate is combined with Fosinopril.Approved
FosinoprilatThe risk or severity of renal failure can be increased when Methyl salicylate is combined with Fosinoprilat.Experimental
FurosemideThe therapeutic efficacy of Furosemide can be decreased when used in combination with Methyl salicylate.Approved, Vet Approved
GabexateThe risk or severity of bleeding can be increased when Methyl salicylate is combined with Gabexate.Investigational
GemigliptinMethyl salicylate may increase the hypoglycemic activities of Gemigliptin.Investigational
Ginkgo bilobaGinkgo biloba may increase the anticoagulant activities of Methyl salicylate.Approved, Investigational, Nutraceutical
GitoformateThe serum concentration of Gitoformate can be decreased when it is combined with Methyl salicylate.Experimental
GlibornurideMethyl salicylate may increase the hypoglycemic activities of Glibornuride.Investigational, Withdrawn
GliclazideMethyl salicylate may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideMethyl salicylate may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideMethyl salicylate may increase the hypoglycemic activities of Glipizide.Approved, Investigational
GliquidoneMethyl salicylate may increase the hypoglycemic activities of Gliquidone.Approved, Investigational
GlisoxepideMethyl salicylate may increase the hypoglycemic activities of Glisoxepide.Investigational
GlyburideMethyl salicylate may increase the hypoglycemic activities of Glyburide.Approved
GlycodiazineMethyl salicylate may increase the hypoglycemic activities of Glycodiazine.Approved, Investigational
GosogliptinMethyl salicylate may increase the hypoglycemic activities of Gosogliptin.Investigational
GuacetisalThe risk or severity of bleeding, nephrotoxicity, and gastrointestinal bleeding can be increased when Guacetisal is combined with Methyl salicylate.Experimental
Guar gumMethyl salicylate may increase the hypoglycemic activities of Guar gum.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Halcinonide.Approved, Investigational, Withdrawn
HalometasoneThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Halometasone.Experimental
HeparinThe risk or severity of bleeding can be increased when Methyl salicylate is combined with Heparin.Approved, Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Methyl salicylate.Approved, Investigational
HydrocortisoneThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Hydrocortisone.Approved, Vet Approved
Hydrocortisone aceponateThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Hydrocortisone aceponate.Experimental, Vet Approved
Hydrocortisone acetateThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Hydrocortisone acetate.Approved, Vet Approved
Hydrocortisone butyrateThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Hydrocortisone butyrate.Approved, Vet Approved
Hydrocortisone probutateThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Hydrocortisone probutate.Approved, Vet Approved
Hydrocortisone succinateThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Hydrocortisone succinate.Approved
Hydrocortisone valerateThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Hydrocortisone valerate.Approved, Vet Approved
HydroxytyrosolThe risk or severity of adverse effects can be increased when Hydroxytyrosol is combined with Methyl salicylate.Investigational
IbudilastThe risk or severity of adverse effects can be increased when Ibudilast is combined with Methyl salicylate.Approved, Investigational
IcosapentThe therapeutic efficacy of Methyl salicylate can be decreased when used in combination with Icosapent.Approved, Nutraceutical
Icosapent ethylThe risk or severity of adverse effects can be increased when Icosapent ethyl is combined with Methyl salicylate.Approved, Investigational, Nutraceutical
IdraparinuxThe risk or severity of bleeding can be increased when Methyl salicylate is combined with Idraparinux.Investigational
IfetrobanThe risk or severity of adverse effects can be increased when Ifetroban is combined with Methyl salicylate.Investigational
IloprostThe risk or severity of bleeding can be increased when Methyl salicylate is combined with Iloprost.Approved, Investigational
ImidaprilThe risk or severity of renal failure can be increased when Methyl salicylate is combined with Imidapril.Investigational
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Methyl salicylate.Investigational
IndomethacinThe therapeutic efficacy of Methyl salicylate can be decreased when used in combination with Indomethacin.Approved, Investigational
Influenza Vaccine (Live/Attenuated)The risk or severity of adverse effects can be increased when Influenza Vaccine (Live/Attenuated) is combined with Methyl salicylate.Approved
Insulin AspartMethyl salicylate may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin BeefMethyl salicylate may increase the hypoglycemic activities of Insulin Beef.Approved
Insulin DegludecMethyl salicylate may increase the hypoglycemic activities of Insulin Degludec.Approved
Insulin DetemirMethyl salicylate may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineMethyl salicylate may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineMethyl salicylate may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanMethyl salicylate may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproMethyl salicylate may increase the hypoglycemic activities of Insulin Lispro.Approved
Insulin peglisproMethyl salicylate may increase the hypoglycemic activities of Insulin peglispro.Investigational
Insulin PorkMethyl salicylate may increase the hypoglycemic activities of Insulin Pork.Approved
KetanserinThe risk or severity of adverse effects can be increased when Ketanserin is combined with Methyl salicylate.Investigational
KetoprofenThe therapeutic efficacy of Methyl salicylate can be decreased when used in combination with Ketoprofen.Approved, Vet Approved
KetorolacThe therapeutic efficacy of Methyl salicylate can be decreased when used in combination with Ketorolac.Approved
KRP-104Methyl salicylate may increase the hypoglycemic activities of KRP-104.Investigational
Lanatoside CThe serum concentration of Lanatoside C can be decreased when it is combined with Methyl salicylate.Experimental
LepirudinThe risk or severity of bleeding can be increased when Methyl salicylate is combined with Lepirudin.Approved
LetaxabanThe risk or severity of bleeding can be increased when Methyl salicylate is combined with Letaxaban.Investigational
LinagliptinMethyl salicylate may increase the hypoglycemic activities of Linagliptin.Approved
LinsidomineThe risk or severity of adverse effects can be increased when Linsidomine is combined with Methyl salicylate.Experimental
LiraglutideMethyl salicylate may increase the hypoglycemic activities of Liraglutide.Approved
LisinoprilThe risk or severity of renal failure can be increased when Methyl salicylate is combined with Lisinopril.Approved, Investigational
LixisenatideMethyl salicylate may increase the hypoglycemic activities of Lixisenatide.Approved
LobeglitazoneMethyl salicylate may increase the hypoglycemic activities of Lobeglitazone.Approved, Investigational
LornoxicamThe therapeutic efficacy of Methyl salicylate can be decreased when used in combination with Lornoxicam.Approved, Investigational
LoteprednolThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Loteprednol.Approved
Magnesium salicylateThe therapeutic efficacy of Methyl salicylate can be decreased when used in combination with Magnesium salicylate.Approved
MecaserminMethyl salicylate may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
Meclofenamic acidThe therapeutic efficacy of Methyl salicylate can be decreased when used in combination with Meclofenamic acid.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Medrysone.Approved
Mefenamic acidThe therapeutic efficacy of Methyl salicylate can be decreased when used in combination with Mefenamic acid.Approved
MelagatranThe risk or severity of bleeding can be increased when Methyl salicylate is combined with Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Melengestrol.Vet Approved
MeloxicamThe therapeutic efficacy of Methyl salicylate can be decreased when used in combination with Meloxicam.Approved, Vet Approved
MeprednisoneThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Meprednisone.Approved, Investigational
MercaptopurineThe metabolism of Mercaptopurine can be decreased when combined with Methyl salicylate.Approved
MesalazineThe risk or severity of bleeding, nephrotoxicity, and gastrointestinal bleeding can be increased when Mesalazine is combined with Methyl salicylate.Approved
MetahexamideMethyl salicylate may increase the hypoglycemic activities of Metahexamide.Experimental
MetforminMethyl salicylate may increase the hypoglycemic activities of Metformin.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Methazolamide.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Methyl salicylate.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Methylprednisolone.Approved, Vet Approved
MetildigoxinThe serum concentration of Metildigoxin can be decreased when it is combined with Methyl salicylate.Experimental
MifepristoneMethyl salicylate may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
MiglitolMethyl salicylate may increase the hypoglycemic activities of Miglitol.Approved
MitiglinideMethyl salicylate may increase the hypoglycemic activities of Mitiglinide.Approved, Investigational
MoexiprilThe risk or severity of renal failure can be increased when Methyl salicylate is combined with Moexipril.Approved
MometasoneThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Mometasone.Approved, Vet Approved
Mometasone furoateThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Mometasone furoate.Approved, Vet Approved
Monopotassium phosphateThe serum concentration of Methyl salicylate can be increased when it is combined with Monopotassium phosphate.Approved, Investigational, Vet Approved
NabumetoneThe therapeutic efficacy of Methyl salicylate can be decreased when used in combination with Nabumetone.Approved
NadroparinThe risk or severity of bleeding can be increased when Methyl salicylate is combined with Nadroparin.Approved, Investigational
NafamostatThe risk or severity of bleeding can be increased when Methyl salicylate is combined with Nafamostat.Approved, Investigational
NaftopidilThe risk or severity of adverse effects can be increased when Naftopidil is combined with Methyl salicylate.Investigational
NaproxenThe therapeutic efficacy of Methyl salicylate can be decreased when used in combination with Naproxen.Approved, Vet Approved
NateglinideMethyl salicylate may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NBI-6024Methyl salicylate may increase the hypoglycemic activities of NBI-6024.Investigational
NepafenacThe therapeutic efficacy of Methyl salicylate can be decreased when used in combination with Nepafenac.Approved, Investigational
NetoglitazoneMethyl salicylate may increase the hypoglycemic activities of Netoglitazone.Experimental
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Methyl salicylate.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Methyl salicylate.Investigational
NN344Methyl salicylate may increase the hypoglycemic activities of NN344.Investigational
OleandrinThe serum concentration of Oleandrin can be decreased when it is combined with Methyl salicylate.Experimental, Investigational
OlsalazineThe risk or severity of bleeding, nephrotoxicity, and gastrointestinal bleeding can be increased when Olsalazine is combined with Methyl salicylate.Approved
OmapatrilatThe risk or severity of renal failure can be increased when Methyl salicylate is combined with Omapatrilat.Investigational
OmarigliptinMethyl salicylate may increase the hypoglycemic activities of Omarigliptin.Investigational
OtamixabanThe risk or severity of bleeding can be increased when Methyl salicylate is combined with Otamixaban.Investigational
OuabainThe serum concentration of Ouabain can be decreased when it is combined with Methyl salicylate.Approved
OxaprozinThe therapeutic efficacy of Methyl salicylate can be decreased when used in combination with Oxaprozin.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Paramethasone.Approved
ParnaparinThe risk or severity of bleeding can be increased when Methyl salicylate is combined with Parnaparin.Approved, Investigational
PentamidineMethyl salicylate may increase the hypoglycemic activities of Pentamidine.Approved, Investigational
Pentosan PolysulfateThe risk or severity of bleeding can be increased when Methyl salicylate is combined with Pentosan Polysulfate.Approved
PentoxifyllineThe risk or severity of adverse effects can be increased when Pentoxifylline is combined with Methyl salicylate.Approved, Investigational
PerindoprilThe risk or severity of renal failure can be increased when Methyl salicylate is combined with Perindopril.Approved
PerindoprilatThe risk or severity of renal failure can be increased when Methyl salicylate is combined with Perindoprilat.Experimental
PeruvosideThe serum concentration of Peruvoside can be decreased when it is combined with Methyl salicylate.Experimental
PhenforminMethyl salicylate may increase the hypoglycemic activities of Phenformin.Approved, Investigational, Withdrawn
PhenindioneMethyl salicylate may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonMethyl salicylate may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
Phenyl aminosalicylateThe risk or severity of bleeding, nephrotoxicity, and gastrointestinal bleeding can be increased when Phenyl aminosalicylate is combined with Methyl salicylate.Approved
PhenylbutazoneThe therapeutic efficacy of Methyl salicylate can be decreased when used in combination with Phenylbutazone.Approved, Vet Approved
PicotamideThe risk or severity of adverse effects can be increased when Picotamide is combined with Methyl salicylate.Experimental
PioglitazoneMethyl salicylate may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PiretanideThe therapeutic efficacy of Piretanide can be decreased when used in combination with Methyl salicylate.Approved
PiroxicamThe therapeutic efficacy of Methyl salicylate can be decreased when used in combination with Piroxicam.Approved, Investigational
Potassium CitrateThe risk or severity of bleeding can be increased when Methyl salicylate is combined with Potassium Citrate.Approved, Investigational, Vet Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Methyl salicylate.Approved, Investigational
PramlintideMethyl salicylate may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PrasugrelThe risk or severity of bleeding can be increased when Methyl salicylate is combined with Prasugrel.Approved
PrednicarbateThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Prednicarbate.Approved, Investigational
PrednisoloneThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Prednisone.Approved, Vet Approved
PrednylideneThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Prednylidene.Experimental
ProbenecidThe therapeutic efficacy of Probenecid can be decreased when used in combination with Methyl salicylate.Approved, Investigational
ProscillaridinThe serum concentration of Proscillaridin can be decreased when it is combined with Methyl salicylate.Experimental
Protein CThe risk or severity of bleeding can be increased when Methyl salicylate is combined with Protein C.Approved
Protein S humanThe risk or severity of bleeding can be increased when Methyl salicylate is combined with Protein S human.Approved
ProtocatechualdehydeThe risk or severity of bleeding can be increased when Methyl salicylate is combined with Protocatechualdehyde.Approved
QuinaprilThe risk or severity of renal failure can be increased when Methyl salicylate is combined with Quinapril.Approved, Investigational
QuinaprilatThe risk or severity of renal failure can be increased when Methyl salicylate is combined with Quinaprilat.Experimental
QuinineMethyl salicylate may increase the hypoglycemic activities of Quinine.Approved
RamatrobanThe risk or severity of adverse effects can be increased when Ramatroban is combined with Methyl salicylate.Investigational
RamiprilThe risk or severity of renal failure can be increased when Methyl salicylate is combined with Ramipril.Approved
RamiprilatThe risk or severity of renal failure can be increased when Methyl salicylate is combined with Ramiprilat.Experimental
RelcovaptanThe risk or severity of adverse effects can be increased when Relcovaptan is combined with Methyl salicylate.Investigational
RepaglinideMethyl salicylate may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
RescinnamineThe risk or severity of renal failure can be increased when Methyl salicylate is combined with Rescinnamine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Methyl salicylate.Approved, Experimental, Investigational
ReteplaseThe risk or severity of bleeding can be increased when Methyl salicylate is combined with Reteplase.Approved, Investigational
ReviparinThe risk or severity of bleeding can be increased when Methyl salicylate is combined with Reviparin.Approved, Investigational
RidogrelThe risk or severity of adverse effects can be increased when Ridogrel is combined with Methyl salicylate.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Rimexolone.Approved
RivaroxabanThe risk or severity of bleeding can be increased when Methyl salicylate is combined with Rivaroxaban.Approved
RivoglitazoneMethyl salicylate may increase the hypoglycemic activities of Rivoglitazone.Experimental, Investigational
RosiglitazoneMethyl salicylate may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
Salicylic acidThe risk or severity of bleeding, nephrotoxicity, and gastrointestinal bleeding can be increased when Salicylic acid is combined with Methyl salicylate.Approved, Investigational, Vet Approved
SalsalateThe therapeutic efficacy of Methyl salicylate can be decreased when used in combination with Salsalate.Approved
SarpogrelateThe risk or severity of adverse effects can be increased when Sarpogrelate is combined with Methyl salicylate.Investigational
SaruplaseThe risk or severity of bleeding can be increased when Methyl salicylate is combined with Saruplase.Experimental
SaxagliptinMethyl salicylate may increase the hypoglycemic activities of Saxagliptin.Approved
SemaglutideMethyl salicylate may increase the hypoglycemic activities of Semaglutide.Approved, Investigational
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Methyl salicylate.Approved, Vet Approved
SitagliptinMethyl salicylate may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
Sodium CitrateThe risk or severity of bleeding can be increased when Methyl salicylate is combined with Sodium Citrate.Approved, Investigational
SotagliflozinMethyl salicylate may increase the hypoglycemic activities of Sotagliflozin.Investigational
SpiraprilThe risk or severity of renal failure can be increased when Methyl salicylate is combined with Spirapril.Approved
StreptokinaseThe risk or severity of bleeding can be increased when Methyl salicylate is combined with Streptokinase.Approved, Investigational
SulfadiazineMethyl salicylate may increase the hypoglycemic activities of Sulfadiazine.Approved, Investigational, Vet Approved
SulfamethoxazoleMethyl salicylate may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfasalazineThe risk or severity of bleeding, nephrotoxicity, and gastrointestinal bleeding can be increased when Sulfasalazine is combined with Methyl salicylate.Approved
SulfinpyrazoneThe risk or severity of adverse effects can be increased when Sulfinpyrazone is combined with Methyl salicylate.Approved
SulfisoxazoleMethyl salicylate may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SulindacThe therapeutic efficacy of Methyl salicylate can be decreased when used in combination with Sulindac.Approved, Investigational
SulodexideThe risk or severity of bleeding can be increased when Methyl salicylate is combined with Sulodexide.Approved, Investigational
SunitinibMethyl salicylate may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
SuprofenThe therapeutic efficacy of Methyl salicylate can be decreased when used in combination with Suprofen.Approved, Withdrawn
TaspoglutideMethyl salicylate may increase the hypoglycemic activities of Taspoglutide.Investigational
TemocaprilThe risk or severity of renal failure can be increased when Methyl salicylate is combined with Temocapril.Experimental, Investigational
TenecteplaseThe risk or severity of bleeding can be increased when Methyl salicylate is combined with Tenecteplase.Approved
TeneligliptinMethyl salicylate may increase the hypoglycemic activities of Teneligliptin.Investigational
TenoxicamThe therapeutic efficacy of Methyl salicylate can be decreased when used in combination with Tenoxicam.Approved
TesmilifeneThe risk or severity of adverse effects can be increased when Tesmilifene is combined with Methyl salicylate.Investigational
Tiaprofenic acidThe therapeutic efficacy of Methyl salicylate can be decreased when used in combination with Tiaprofenic acid.Approved
TicagrelorThe risk or severity of bleeding can be increased when Methyl salicylate is combined with Ticagrelor.Approved
TiclopidineThe risk or severity of adverse effects can be increased when Ticlopidine is combined with Methyl salicylate.Approved
TinzaparinThe risk or severity of bleeding can be increased when Methyl salicylate is combined with Tinzaparin.Approved
TioclomarolMethyl salicylate may increase the anticoagulant activities of Tioclomarol.Experimental
TioguanineThe metabolism of Tioguanine can be decreased when combined with Methyl salicylate.Approved
TirofibanThe risk or severity of adverse effects can be increased when Tirofiban is combined with Methyl salicylate.Approved
TixocortolThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Tixocortol.Approved, Withdrawn
TocopherylquinoneThe risk or severity of bleeding can be increased when Methyl salicylate is combined with Tocopherylquinone.Experimental, Investigational
TolazamideMethyl salicylate may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
TolbutamideMethyl salicylate may increase the hypoglycemic activities of Tolbutamide.Approved, Investigational
TolmetinThe therapeutic efficacy of Methyl salicylate can be decreased when used in combination with Tolmetin.Approved
TorasemideThe therapeutic efficacy of Torasemide can be decreased when used in combination with Methyl salicylate.Approved
TrandolaprilThe risk or severity of renal failure can be increased when Methyl salicylate is combined with Trandolapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Methyl salicylate.Approved, Investigational
TrapidilThe risk or severity of adverse effects can be increased when Trapidil is combined with Methyl salicylate.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Methyl salicylate.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Triamcinolone.Approved, Vet Approved
TriflusalThe risk or severity of bleeding can be increased when Methyl salicylate is combined with Triflusal.Approved, Investigational
TrilostaneThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Trilostane.Approved, Investigational, Vet Approved, Withdrawn
TroglitazoneMethyl salicylate may increase the hypoglycemic activities of Troglitazone.Investigational, Withdrawn
Trolamine salicylateThe risk or severity of bleeding, nephrotoxicity, and gastrointestinal bleeding can be increased when Methyl salicylate is combined with Trolamine salicylate.Approved
TroxerutinThe risk or severity of bleeding can be increased when Methyl salicylate is combined with Troxerutin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Ulobetasol.Approved
UrokinaseThe risk or severity of bleeding can be increased when Methyl salicylate is combined with Urokinase.Approved, Investigational, Withdrawn
Valproic AcidThe serum concentration of Valproic Acid can be increased when it is combined with Methyl salicylate.Approved, Investigational
Varicella Zoster Vaccine (Live/Attenuated)The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Varicella Zoster Vaccine (Live/Attenuated).Approved
VerapamilVerapamil may increase the anticoagulant activities of Methyl salicylate.Approved
VildagliptinMethyl salicylate may increase the hypoglycemic activities of Vildagliptin.Approved, Investigational
VogliboseMethyl salicylate may increase the hypoglycemic activities of Voglibose.Approved, Investigational
VorapaxarThe risk or severity of bleeding can be increased when Methyl salicylate is combined with Vorapaxar.Approved
WarfarinMethyl salicylate may increase the anticoagulant activities of Warfarin.Approved
XimelagatranThe risk or severity of bleeding can be increased when Methyl salicylate is combined with Ximelagatran.Approved, Investigational, Withdrawn
ZofenoprilThe risk or severity of renal failure can be increased when Methyl salicylate is combined with Zofenopril.Experimental
Food Interactions
Not Available

References

General References
  1. He YY, Yan Y, Zhang HF, Lin YH, Chen YC, Yan Y, Wu P, Fang JS, Yang SH, Du GH: Methyl salicylate 2-O-beta-d-lactoside alleviates the pathological progression of pristane-induced systemic lupus erythematosus-like disease in mice via suppression of inflammatory response and signal transduction. Drug Des Devel Ther. 2016 Sep 29;10:3183-3196. eCollection 2016. [PubMed:27729775]
  2. Xin W, Huang C, Zhang X, Xin S, Zhou Y, Ma X, Zhang D, Li Y, Zhou S, Zhang D, Zhang T, Du G: Methyl salicylate lactoside inhibits inflammatory response of fibroblast-like synoviocytes and joint destruction in collagen-induced arthritis in mice. Br J Pharmacol. 2014 Jul;171(14):3526-38. doi: 10.1111/bph.12715. [PubMed:24712652]
  3. Mason L, Moore RA, Edwards JE, McQuay HJ, Derry S, Wiffen PJ: Systematic review of efficacy of topical rubefacients containing salicylates for the treatment of acute and chronic pain. BMJ. 2004 Apr 24;328(7446):995. Epub 2004 Mar 19. [PubMed:15033879]
  4. Higashi Y, Kiuchi T, Furuta K: Efficacy and safety profile of a topical methyl salicylate and menthol patch in adult patients with mild to moderate muscle strain: a randomized, double-blind, parallel-group, placebo-controlled, multicenter study. Clin Ther. 2010 Jan;32(1):34-43. doi: 10.1016/j.clinthera.2010.01.016. [PubMed:20171409]
  5. Derry S, Matthews PR, Wiffen PJ, Moore RA: Salicylate-containing rubefacients for acute and chronic musculoskeletal pain in adults. Cochrane Database Syst Rev. 2014 Nov 26;(11):CD007403. doi: 10.1002/14651858.CD007403.pub3. [PubMed:25425092]
  6. Moore RA, Derry S, McQuay HJ: Topical analgesics for acute and chronic pain in adults. Cochrane Database Syst Rev. 2010;(7). pii: CD008609. [PubMed:25411557]
  7. Thompson TM, Toerne T, Erickson TB: Salicylate Toxicity from Genital Exposure to a Methylsalicylate-Containing Rubefacient. West J Emerg Med. 2016 Mar;17(2):181-3. doi: 10.5811/westjem.2016.1.29262. Epub 2016 Mar 2. [PubMed:26973745]
  8. FDA SALONPAS® Pain Relief Patch Clinical Review [Link]
  9. Norwegian Food Safety Authority: Methyl salicylate risk review [Link]
External Links
Human Metabolome Database
HMDB0034172
KEGG Drug
D01087
KEGG Compound
C12305
PubChem Compound
4133
PubChem Substance
347827876
ChemSpider
13848808
ChEBI
31832
ChEMBL
CHEMBL108545
Drugs.com
Drugs.com Drug Page
Wikipedia
Methyl_salicylate
AHFS Codes
  • 28:08.04.24 — Salicylates
MSDS
Download (55.2 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2WithdrawnTreatmentPain, Acute1
2, 3WithdrawnTreatmentHuman Immunodeficiency Virus Infection(HIV)/Acquired Immunodeficiency Syndrome (AIDS) / Immune Reconstitution Inflammatory Syndrome / Immune Reconstitution Syndrome / Tuberculosis1
4CompletedPreventionNeonatal Infections1
4CompletedTreatmentPeriodontitis, Aggressive1
4CompletedTreatmentSub-acute Back Pain1
4RecruitingTreatmentChronic Low Back Pain (CLBP)2
Not AvailableRecruitingTreatmentPeriodontitis / Type 2 Diabetes Mellitus1
Not AvailableUnknown StatusTreatmentPain1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Aerosol, sprayCutaneous; Topical; Transdermal
RinseOral
SprayTopical23 g/100g
MouthwashBuccal
SolutionTopical
OilPercutaneous; Topical; Transdermal
PowderTopical
LotionTopical10 g/g
LotionTopical10 g/100mL
SprayTopical
GelTopical
SalveTopical
LiquidTopical
OilTopical
OintmentTopical
CreamTopical250 mg/mL
PatchCutaneous; Topical; Transdermal
PasteTopical
LiquidTopical980 mg/mL
SolutionTransdermal3 g/100mL
LiquidOral
StickTopical
OilTopical60 g/100mL
OintmentTopical13.5 g/100g
KitOral; Topical
LiquidRespiratory (inhalation)
OintmentTopical10.5 g/100g
OilTopical105 mg/mL
PatchTopical
LotionTopical
MouthwashOral
LinimentTopical
JellyNasal
GelTopical105 mg/g
LotionTopical20 g/100g
EmulsionTopical
LiquidTopical40 g/100mL
GelPercutaneous; Topical; Transdermal
PatchPercutaneous; Topical; Transdermal
Aerosol, sprayPercutaneous; Topical; Transdermal
Aerosol, foamPercutaneous; Topical; Transdermal
PlasterTransdermal
PlasterTopical
LiquidCutaneous; Topical; Transdermal
Kit
LiquidTopical10 g/100g
PatchTopical10 mg/100mg
PatchTopical10 g/100g
MouthwashDental
EmulsionTopical10 %
CreamTopical100 mg/g
PatchTransdermal
GelTopical100 mg/g
OintmentTopical10.5 g/90g
OintmentTopical15.75 g/150g
CreamTopical
OilTransdermal
LiquidTopical
PlasterTopical; Transdermal
PoulticeTransdermal160 mg/17g
PoulticeTransdermal105 mg/17.5g
LiquidTopical200 mg/g
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US8809615No2010-01-032030-01-03Us
US9233184No2007-08-012027-08-01Us

Properties

State
Liquid
Experimental Properties
PropertyValueSource
melting point (°C)-8.6MSDS
boiling point (°C)220-224MSDS
water solubilitySlightly solubleMSDS
logP2.5MSDS
Predicted Properties
PropertyValueSource
Water Solubility5.73 mg/mLALOGPS
logP2.07ALOGPS
logP2.32ChemAxon
logS-1.4ALOGPS
pKa (Strongest Acidic)9.72ChemAxon
pKa (Strongest Basic)-4.3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area46.53 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity40.06 m3·mol-1ChemAxon
Polarizability14.98 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-00dl-9800000000-4c121b87ee97a30f4150
GC-MS Spectrum - EI-BGC-MSsplash10-00dl-9800000000-aeff759175e190d33827
GC-MS Spectrum - EI-BGC-MSsplash10-00dl-9700000000-8449a003796d4c61d429
Mass Spectrum (Electron Ionization)MSsplash10-00dl-9800000000-1d56d6cf07db519b50e2
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0udi-0900000000-eba52e49290e16ea60c0
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0uk9-0900000000-684f1c8a3cf324183257
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0uk9-9300000000-a594ffaab84fc15a2edc
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0udi-0900000000-76d5fc81bafad7c2222c
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0udi-0900000000-dae7a80af6333acd66fc
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0gb9-9600000000-09304803bc773495c704
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-0fk9-3900000000-e2029bf3c75775175ff3
1H NMR Spectrum1D NMRNot Applicable
13C NMR Spectrum1D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as o-hydroxybenzoic acid esters. These are benzoic acid esters where the benzene ring is ortho-substituted with a hydroxy group.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzoic acids and derivatives
Direct Parent
o-Hydroxybenzoic acid esters
Alternative Parents
Salicylic acid and derivatives / Benzoyl derivatives / 1-hydroxy-4-unsubstituted benzenoids / 1-hydroxy-2-unsubstituted benzenoids / Vinylogous acids / Methyl esters / Monocarboxylic acids and derivatives / Organooxygen compounds / Organic oxides / Hydrocarbon derivatives
Substituents
O-hydroxybenzoic acid ester / Salicylic acid or derivatives / Benzoyl / 1-hydroxy-4-unsubstituted benzenoid / 1-hydroxy-2-unsubstituted benzenoid / Phenol / Vinylogous acid / Methyl ester / Carboxylic acid ester / Carboxylic acid derivative
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
salicylates, benzoate ester (CHEBI:31832) / a small molecule (CPD-6442)

Drug created on November 30, 2015 12:10 / Updated on August 14, 2018 04:32